All Stories
Clasp Therapeutics took off with $150 million in Series A financing to develop a portfolio of next-generation immunotherapies that are both personalized and off-the-shelf to target hard-to-treat tumors. Based in Cambridge, Massachusetts and Rockville, Maryland, the startup garnered attention from…
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital. Portal is implementing a simplified approach to intracellular delivery, focused on accelerating advances in RNA,…
MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver cancer…
Zymergen has raised $300 million in financing. The investment total, announced yesterday, includes Series D funding led by Baillie Gifford, and joined by Baron Capital Group and one of the world’s largest sovereign wealth funds, as well as additional growth…
